Valuation: Faeth Therapeutics, Inc.

Market Cap 517M 460M 421M 383M 723M 48.81B 742M 5.06B 2.02B 25.85B 1.94B 1.9B 81.58B P/E 2026 *
-1.68x
P/E 2027 * -5.89x
Enterprise Value 517M 460M 421M 383M 723M 48.81B 742M 5.06B 2.02B 25.85B 1.94B 1.9B 81.58B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.04%
Yield 2026 *
-
Yield 2027 * -
1 day-3.58%
1 week+2.77%
Current month+3.10%
1 month-28.89%
3 months-21.63%
6 months-25.48%
Current year+80.60%
1 week 17.88
Extreme 17.88
20.44
1 month 16.57
Extreme 16.57
29.64
Current year 8.37
Extreme 8.37
42.14
1 year 7.45
Extreme 7.45
42.14
3 years 5
Extreme 5
42.14
5 years 5
Extreme 5
202
10 years 5
Extreme 5
530
Manager TitleAgeSince
Chief Executive Officer 40 2026-06-12
Director of Finance/CFO 45 2026-06-12
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 62 2024-12-31
Director/Board Member 72 2014-12-31
Director/Board Member 51 2021-07-29
Date Insider Type Main position Quantity % Market Cap. Importance
9/11/26 Other

Director

42,631 0.1654%
9/11/26 Free

Director

25,000 0.0970%
7/21/26 Free

Chief Executive Officer

398,018 1.5440%
Change 5-day change 1-year change 3-year change Capi.($)
-3.58%+2.77%+117.25%+27.62% 517M
+3.80%+8.47%+64.65%+77.70% 66.87B
+1.63%+4.93%+24.89%+102.90% 56.55B
+0.07%+1.39%+12.75%+76.61% 57.2B
-0.95%-4.29%+25.30%+32.70% 43.47B
-6.59%-1.41%+216.14%+770.91% 42.8B
+3.54%+5.28%+21.72%+99.44% 42.95B
+1.59%-4.04%+97.66%+81.57% 32.11B
+7.50%+13.28%+28.05%+64.46% 34.01B
-3.35%-4.44%-42.94%+347.27% 24.13B
Average +0.39%+3.99%+56.54%+168.12% 40.06B
Weighted average by Cap. +1.04%+3.91%+52.06%+167.98%

Financials

2026 *2027 *
Net sales - -
Net income -229M -204M -187M -170M -321M -21.66B -329M -2.24B -898M -11.47B -860M -842M -36.2B -103M -91.39M -83.59M -76.13M -144M -9.69B -147M -1B -402M -5.13B -385M -377M -16.2B
Net Debt - -
Projected Income Statement - Annual - Faeth Therapeutics, Inc.
Logo Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.
Employees
29
Date Price Change Volume
26-11-05 US$19.48 -2.55% 110,273
26-11-04 US$19.99 +1.73% 237,138
26-11-03 US$19.65 +2.18% 203,274
26-11-02 US$19.23 +2.89% 212,607
26-10-30 US$18.69 -0.32% 510,969
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Faeth Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
19.99USD
Average target price
55.31USD
Spread / Average Target
+176.68%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Faeth Therapeutics, Inc.